TMPRSS2 and prostate carcinoma: About 90% of gene fusions in prostate cancer are accounted by the fusion between the transmembrane protease, serine 2 (TMPRSS2), that is a strong androgen-regulated gene and the ERG gene, a v-ets erythroblastosis virus E26 oncogene homolog (avian).